The company will use the new funds to accelerate development of its pipeline and expand its mutation, allostery and pharmacology, or MAP, computational and discovery platform. The platform is designed to identify allosteric oncogenic mutations.
The company also plans to establish its new corporate headquarters in Cambridge, Mass., as well as advance two or three existing development candidates into the clinic over the next two years.
New Enterprise Associates and RA Capital Management led the latest investment round. In all, Black Diamond Therapeutics has raised $105 million so far.
More articles on data analytics and precision medicine:
NIH’s ‘All of Us’ establishes 3 genome centers with $29M
Peter Thiel’s data-mining company Palantir wins $7M NIH contract
Social determinants of health data doesn’t improve health predictions, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
